Two more biotech birds queue up IPOs while the window is open
This article was originally published in Scrip
Executive Summary
An initial public offering window is open and won't be closing soon, according to newly-public Regulus Therapeutics' president and CEO Kleanthis Xanthopoulos, and two more biotech birds have set price ranges for their IPOs in hopes of flying the private company coop.